Trial Profile
A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 15 Dec 2015 Results of open-label extension study published in The Journal of Rheumatology
- 15 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.